Mirum Pharmaceuticals Inc (MIRM)
NASDAQ:MIRM
MIRM Stock Chart & Stats
$96.90
-$0.27(-0.64%)
At close: 4:00 PM EST
$96.90
-$0.27(-0.64%)
Day’s Range― - ―
52-Week Range$37.83 - $109.28
Previous CloseN/A
Volume92.82K
Average Volume (3M)911.91K
Market Cap
$5.82B
Enterprise Value$4.89B
Total Cash (Recent Filing)$383.33M
Total Debt (Recent Filing)$319.45M
Price to Earnings (P/E)―
Beta0.78
Next Earnings
Apr 30, 2026EPS Estimate
-0.34Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.10
Shares Outstanding60,341,618
10 Day Avg. Volume704,118
30 Day Avg. Volume911,908
Financial Highlights & Ratios
PEG Ratio2.28
Price to Book (P/B)12.60
Price to Sales (P/S)7.61
P/FCF Ratio72.26
Enterprise Value/Market Cap0.84
Enterprise Value/Revenue9.37
Enterprise Value/Gross Profit11.61
Enterprise Value/Ebitda350.20
Forecast
1Y Price Target
$129.50Price Target Upside33.64% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering8
EPS Forecast (FY)-1.62
Revenue Forecast (FY)$644.90M
Bulls Say, Bears Say
Bulls Say
Clinical Efficacy AdvantageInterim data indicating a larger placebo-adjusted reduction in itch for volixibat versus an approved therapy suggest potential best-in-class efficacy that could drive uptake if confirmed in pivotal trials.
Commercial Franchise ExpansionStrong Livmarli sales combined with tablet approval that expands use beyond pediatric liquid formulation could broaden the customer base and improve treatment adherence, supporting revenue growth.
Mechanism ValidationApproval of a competing bile acid transporter inhibitor validates the drug-class mechanism and increases confidence that volixibat can address itch in cholestatic liver disease.
Bears Say
Patient Identification And Enrollment ConstraintsChallenges in identifying eligible patients could constrain trial enrollment and slow commercial uptake, increasing execution risk for both development programs and the marketed franchise.
Regulatory Approval UncertaintyLikelihood that regulators will require a confirmatory late-stage study introduces approval timing uncertainty and extends development risk for pruritus indications.
Tolerability RiskA somewhat higher rate of diarrhea with volixibat compared with a competitor creates a tolerability concern that could reduce patient persistence and limit prescribing despite most events being mild to moderate.
Mirum Pharmaceuticals News
MIRM FAQ
What was Mirum Pharmaceuticals Inc’s price range in the past 12 months?
Mirum Pharmaceuticals Inc lowest stock price was $37.83 and its highest was $109.28 in the past 12 months.
What is Mirum Pharmaceuticals Inc’s market cap?
Mirum Pharmaceuticals Inc’s market cap is $5.82B.
When is Mirum Pharmaceuticals Inc’s upcoming earnings report date?
Mirum Pharmaceuticals Inc’s upcoming earnings report date is Apr 30, 2026 which is in 15 days.
How were Mirum Pharmaceuticals Inc’s earnings last quarter?
Mirum Pharmaceuticals Inc released its earnings results on Feb 25, 2026. The company reported -$0.1 earnings per share for the quarter, missing the consensus estimate of $0.056 by -$0.156.
Is Mirum Pharmaceuticals Inc overvalued?
According to Wall Street analysts Mirum Pharmaceuticals Inc’s price is currently Undervalued.
Does Mirum Pharmaceuticals Inc pay dividends?
Mirum Pharmaceuticals Inc does not currently pay dividends.
What is Mirum Pharmaceuticals Inc’s EPS estimate?
Mirum Pharmaceuticals Inc’s EPS estimate is -0.34.
How many shares outstanding does Mirum Pharmaceuticals Inc have?
Mirum Pharmaceuticals Inc has 60,341,618 shares outstanding.
What happened to Mirum Pharmaceuticals Inc’s price movement after its last earnings report?
Mirum Pharmaceuticals Inc reported an EPS of -$0.1 in its last earnings report, missing expectations of $0.056. Following the earnings report the stock price went down -15.126%.
Which hedge fund is a major shareholder of Mirum Pharmaceuticals Inc?
Currently, no hedge funds are holding shares in MIRM
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Mirum Pharmaceuticals Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$129.50 (33.64% Upside)
$129.50 (33.64% Upside)
Blogger Sentiment
Bullish
MIRM Sentiment 100%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 273.8K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $7.8M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 0.2%
Last 30 Days ▲ 6.1%
Last 30 Days ▲ 6.1%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
143.78%
12-Months-Change
Fundamentals
Return on Equity
-8.53%
Trailing 12-Months
Asset Growth
25.65%
Trailing 12-Months
Company Description
Mirum Pharmaceuticals Inc
Mirum Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. The company's lead product candidate is LIVMARLI, an investigational oral drug for the treatment of progressive familial intrahepatic cholestasis disease, as well as for the treatment of Alagille syndrome and biliary atresia disease. It also develops Volixibat drug for treatment of intrahepatic cholestasis of pregnancy and primary sclerosing cholangitis. Mirum Pharmaceuticals, Inc. was incorporated in 2018 and is headquartered in Foster City, California.
MIRM Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call presents a largely positive operational and commercial story: strong 2025 revenue growth (55% YoY), improved commercial margins (~55%), a healthy cash position and successful financing, multiple regulatory approvals, and an expanded pipeline with several near-term potentially registrational readouts. Key risks include a planned material increase in R&D spend (approximately $150M tied to brolobitug) compressing expenses into 2026, a deceleration in revenue growth implied by 2026 guidance (~21%–25% vs 55% in 2025), some region-specific revenue headwinds (Japan), and clinical/regulatory and competitive uncertainties for upcoming programs. Overall, the company appears well funded and operationally strong but will face elevated near-term spend and execution risk around trial readouts and regulatory interactions.View all MIRM earnings summariesMIRM Stock 12 Month Forecast
Average Price Target
$129.50
▲(33.64% Upside)
Technical Analysis
Arrowhead Pharmaceuticals
―
Catalyst Pharma
―
Ultragenyx Pharmaceutical
―
ImmunityBio
―
Apellis Pharmaceuticals
―
Ownership Overview
Currently, No data available
---